Vismodegib (NCT02523014)

Name: Vismodegib trial for Intracranial Meningioma (NCT02523014)
Uploaded: 2026-10-31T22:15:20.471Z
Duration: 1 min 35 s
Description: Vismodegib trial for Intracranial Meningioma (NCT02523014). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT02523014.

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas: a one-minute explainerNCT025230141 min

Vismodegib trial for Intracranial Meningioma (NCT02523014). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with growing or qualifying residual meningioma and centrally confirmed genetic changes. Current treatment groups require AKT1, PIK3CA or PTEN mutations, or specified CDK-pathway or NF2 alterations.

The idea: match oral treatment to the tumor’s altered growth pathway. Capivasertib targets AKT; abemaciclib targets CDK activity. These drugs aim to block signals needed for tumor growth. Molecular testing determines treatment. Researchers assess response and six-month progression-free survival. The vismodegib and GSK2256098 groups are closed.

This phase 2 study plans 124 patients. Alliance sponsors it across 413 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.